Renal replacement therapy in Europe: A summary of the 2013 ERA-EDTA Registry Annual Report with a focus on diabetes mellitus

Anneke Kramer*, Maria Pippias, Vianda S. Stel, Marjolein Bonthuis, José Maria Abad Diez, Nikolaos Afentakis, Ramón Alonso De La Torre, Patrice Ambuhl, Boris Bikbov, Encarnación Bouzas Caamaño, Ivan Bubic, Jadranka Buturovic-Ponikvar, Fergus J. Caskey, Pablo Castro De La Nuez, Harijs Cernevskis, Frederic Collart, Jordi Comas Farnés, Maria De Los Ángeles Garcia Bazaga, Johan De Meester, Manuel Ferrer AlamarPatrik Finne, Liliana Garneata, Eliezer Golan, James G. Heaf, Marc Hemmelder, Kyriakos Ioannou, Nino Kantaria, Mykola Kolesnyk, Reinhard Kramar, Mathilde Lassalle, Visnja Lezaic, Frantisek Lopot, Fernando MacÁrio, Angela Magaz, Eduardo Martín-Escobar, Wendy Metcalfe, Mai Ots-Rosenberg, Runolfur Palsson, Celestino Piñera Celestino, Halima Resic, Boleslaw Rutkowski, Carmen Santiuste De Pablos, Viera Spustová, Maria Stendahl, Ariana Strakosha, Gültekin Süleymanlar, Marta Torres Guinea, Anna Varberg Reisæter, Evgueniy Vazelov, Edita Ziginskiene, Ziad A. Massy, Christoph Wanner, Kitty J. Jager, Marlies Noordzij

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

73 Scopus citations


Background: This article provides a summary of the 2013 European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report (available at, with a focus on patients with diabetes mellitus (DM) as the cause of end-stage renal disease (ESRD). Methods: In 2015, the ERA-EDTA Registry received data on renal replacement therapy (RRT) for ESRD from 49 national or regional renal registries in 34 countries in Europe and bordering the Mediterranean Sea. Individual patient datawere provided by 31 registries, while 18 registries provided aggregated data. The total population covered by the participating registries comprised 650 million people. Results: In total, 72 933 patients started RRT for ESRD within the countries and regions reporting to the ERA-EDTA Registry, resulting in an overall incidence of 112 per million population (pmp). The overall prevalence on 31 December 2013was 738 pmp (n = 478 990). Patients with DM as the cause of ESRD comprised 24% of the incident RRT patients (26 pmp) and 17% of the prevalent RRT patients (122 pmp).Whencompared with the USA, the incidence of patients starting RRTpmpsecondary toDMin Europe was five times lower and the incidence of RRT due to other causes of ESRD was two times lower. Overall, 19 426 kidney transplants were performed (30 pmp). The 5-year adjusted survival for all RRT patients was 60.9% [95% confidence interval (CI) 60.5-61.3] and 50.6% (95% CI 49.9-51.2) for patients with DM as the cause of ESRD.

Original languageEnglish
Pages (from-to)457-469
Number of pages13
JournalCKJ: Clinical Kidney Journal
Issue number3
StatePublished - Jun 2016
Externally publishedYes


  • End-stage renal disease
  • Incidence
  • Prevalence
  • Renal replacement therapy
  • Survival


Dive into the research topics of 'Renal replacement therapy in Europe: A summary of the 2013 ERA-EDTA Registry Annual Report with a focus on diabetes mellitus'. Together they form a unique fingerprint.

Cite this